Haleon outlines India investment push, shares under mixed analyst scrutiny

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:57.

Haleon plc (GB00BMX86B70) is stepping up its presence in India with a planned investment of around GBP 175 million in rural healthcare access. The London-listed consumer health group, whose primary shares trade on the London Stock Exchange alongside peers such as GSK and Sanofi, pairs this expansion move with a still cautious analyst backdrop according to recent updates.

India expansion plan in focus

According to a detailed report on Haleon’s strategic initiatives, the company plans to deploy roughly GBP 175 million (about USD 233 million) to strengthen its footprint in India, with a focus on underserved rural regions. This investment is aimed at scaling distribution and awareness for over-the-counter and oral health products, a segment where Haleon already holds strong brands.

The initiative follows Haleon’s earlier communication that India is a vital growth market for its portfolio, reflecting rising disposable incomes and increasing health awareness in the country. The company has highlighted that better access to consumer health products in rural areas can support both public health outcomes and long-term category growth, aligning with broader trends seen at competitors like Unilever and Procter & Gamble in emerging markets.

Analyst views remain divided

On the analyst side, sentiment around Haleon shares is mixed. On June 16, Edward Lewis at Rothschild & Co Redburn downgraded Haleon from Buy to Neutral and set a price target of 365 GBp, citing a more balanced risk-reward profile for the stock. MarketScreener data shows that on June 18 this downgrade was recorded among recent broker actions on Haleon.

At the same time, other houses remain constructive. AlphaValue/Baader Europe reiterated a Buy rating on Haleon on June 3, indicating confidence in the group’s medium-term earnings growth trajectory, while Berenberg in early May adjusted its forecasts after a weak start to the year but still kept a Buy recommendation in place. Across the covered brokers the average recommendation sits at "Accumulate" and the median price target is around 4,136 GBp compared with a last closing price of 3,482 GBp, implying roughly 18.8 percent upside potential based on that consensus snapshot.

What the company sells

Haleon’s core business is consumer health, with leading positions in oral care, pain relief and respiratory brands. A representative product is the antacid line Tums, which the company has recently had to recall in certain batches due to foreign particles according to newsflow earlier this month. Alongside Tums, brands such as Sensodyne and Voltaren illustrate Haleon’s focus on everyday health categories where brand loyalty and shelf presence are central to margins and cash flow.

Where the stock trades today

Haleon shares (GB00BMX86B70) trade on the London Stock Exchange under the ticker HLN. As of 2026-06-26, 09:30 London time, the shares last changed hands at approximately 348.2 GBp in sterling terms, based on recent quote data for the Haleon listing.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data and assessments are based on sources believed to be reliable at the time of writing, but cannot be guaranteed. Readers should conduct their own research or consult a professional advisor before making investment decisions.